Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

ABSTRACT: Intervention name : Bevacizumab Dosage And administration of the intervention : Injection Primary outcome(s): Initial safety, PK parameter of bevacizumab Study Design: Open, Single Arm study

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2609866 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR